The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.

Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.

Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.

A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.